What topics does this cannabis study cover?

This study covers research on: Nausea.

Where was this research published?

Published in American journal of public health on October 1, 2026.

Nausea

US survey finds CHS-like symptoms reported by some daily cannabis users

Q: What did this research study find?

**2.7% of all respondents** reported CHS-like symptoms in the national survey.

Prevalence and Correlates of Symptoms of Cannabinoid Hyperemesis Syndrome in the United States, 2025.

American journal of public health • October 1, 2026 • Highly Relevant

🤖

AI Summary

This study asked how common cannabinoid hyperemesis syndrome (CHS)-like symptoms are in the United States and what characteristics are associated with them. Researchers analyzed a nationally representative survey of 7,034 US adults conducted from May to September 2025, comparing groups defined by reported CHS-like symptoms and cannabis-use patterns. Overall, 2.7% of respondents reported CHS-like symptoms; among respondents who used cannabis daily, 17.8% did so.

People who were younger, female, identified as non-White, had lower income or educational attainment, or reported more cannabis use-related problems were more likely to be in the CHS-symptom group than in the daily-use group. The authors conclude that these symptoms are not uncommon and may become more common as cannabis use increases. This is an observational survey, so it shows associations, not causes; the abstract also cannot establish clinical CHS diagnoses or determine why symptoms occurred. This is an abstract-based summary, not a review of the full text.

💡 Key Findings

2.7% of all respondents reported CHS-like symptoms in the national survey.

High

95%

Among respondents who used cannabis daily, 17.8% reported CHS-like symptoms.

High

95%

Younger, female, non-White, lower-income, and less-educated respondents, as well as those reporting more cannabis use-related problems, were more likely to be in the CHS-symptom group than the daily-cannabis-use group. These are associations, not evidence of cause and effect.

High

90%

📄 Original Abstract

Objectives. To characterize the potential prevalence of cannabinoid hyperemesis syndrome (CHS) symptoms and associated characteristics. Methods. Using data from a nationally representative survey of 7034 US adults (conducted May‒September 2025), we fit separate survey-weighted multinomial logistic regression models with a 4-category CHS-symptom and cannabis-use group variable as the outcome and demographic characteristics, cannabis-use behaviors, and cannabis use‒related problems as predictors. Results. Overall, 2.7% of all respondents and 17.8% of respondents who used cannabis daily reported CHS-like symptoms. Respondents who were younger, female, identified as non-White, had lower income, had lower educational attainment, and endorsed cannabis use‒related problems were more likely to be in the CHS-symptom group than in the daily-cannabis-use group. Conclusions. CHS symptoms are not uncommon in the United States, and those with fewer economic resources and more cannabis use‒related problems were more likely to report these symptoms, even compared with others with daily cannabis use. Public Health Implications. As cannabis use increases, CHS is also likely to become more common, underscoring the importance of expanded education about the identification and treatment of CHS. (Am J Public Health. Published online ahead of print October 1, 2026:e1-e10. https://doi.org/10.2105/AJPH.2026.308753).

Paper Type

📄 Research

Publication

Journal: American journal of public health
Published: October 1, 2026
PMID: 42821817
DOI: 10.2105/AJPH.2026.308753

Authors (5)

Mark A Ilgen Mark A. Ilgen is with the Addiction Center in the Department of Psychiatry at the University of Michigan, and the Center for Clinical Management Research at the Ann Arbor VA Healthcare System, Ann Arbor, MI. Amanda M. Price, Blair J. Whittington, and Brian M. Hicks are with the Addiction Center in the Department of Psychiatry at the University of Michigan. Paula Goldman is in the Department of Psychiatry and the Department of Pediatrics at the University of Michigan.
Amanda M Price Mark A. Ilgen is with the Addiction Center in the Department of Psychiatry at the University of Michigan, and the Center for Clinical Management Research at the Ann Arbor VA Healthcare System, Ann Arbor, MI. Amanda M. Price, Blair J. Whittington, and Brian M. Hicks are with the Addiction Center in the Department of Psychiatry at the University of Michigan. Paula Goldman is in the Department of Psychiatry and the Department of Pediatrics at the University of Michigan.
Paula Goldman Mark A. Ilgen is with the Addiction Center in the Department of Psychiatry at the University of Michigan, and the Center for Clinical Management Research at the Ann Arbor VA Healthcare System, Ann Arbor, MI. Amanda M. Price, Blair J. Whittington, and Brian M. Hicks are with the Addiction Center in the Department of Psychiatry at the University of Michigan. Paula Goldman is in the Department of Psychiatry and the Department of Pediatrics at the University of Michigan.
Blair J Whittington Mark A. Ilgen is with the Addiction Center in the Department of Psychiatry at the University of Michigan, and the Center for Clinical Management Research at the Ann Arbor VA Healthcare System, Ann Arbor, MI. Amanda M. Price, Blair J. Whittington, and Brian M. Hicks are with the Addiction Center in the Department of Psychiatry at the University of Michigan. Paula Goldman is in the Department of Psychiatry and the Department of Pediatrics at the University of Michigan.
Brian M Hicks Mark A. Ilgen is with the Addiction Center in the Department of Psychiatry at the University of Michigan, and the Center for Clinical Management Research at the Ann Arbor VA Healthcare System, Ann Arbor, MI. Amanda M. Price, Blair J. Whittington, and Brian M. Hicks are with the Addiction Center in the Department of Psychiatry at the University of Michigan. Paula Goldman is in the Department of Psychiatry and the Department of Pediatrics at the University of Michigan.